Prime Medicine (PRME) Operating Leases (2021 - 2026)
Prime Medicine's (PRME) quarterly Operating Leases came in at $114.5 million in Q1 2026, up 1982.04% YoY from $5.5 million in Q1 2025, and up 5.75% on a QoQ basis from $108.3 million in Q4 2025.
Prime Medicine (PRME) Operating Leases (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Operating Leases data on file, last reported at $114.5 million in Q1 2026.
- Quarterly Operating Leases rose 1982.04% year-over-year to $114.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.5 million (up 1982.04% YoY) and the FY2025 annual result came in at $108.3 million, up 191.26% from the prior year.
- Operating Leases improved to $114.5 million in Q1 2026, from $108.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $118.1 million in Q3 2025 to a low of $4.4 million in Q4 2023.
- A 5-year average of $47.5 million and a median of $33.6 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2025 — Operating Leases slumped 83.63% — and 2026, when it soared 1982.04%.
- Tracing PRME's Operating Leases over 5 years: stood at $17.1 million in 2022, then sank by 74.45% to $4.4 million in 2023, then surged by 753.34% to $37.2 million in 2024, then surged by 191.26% to $108.3 million in 2025, then rose by 5.75% to $114.5 million in 2026.
- The last three Operating Leases figures came in at $114.5 million (Q1 2026), $108.3 million (Q4 2025), and $118.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112.48 Mn |
| Mar 31, 2026 | 114.51 Mn |
| Dec 31, 2025 | 108.29 Mn |
| Sep 30, 2025 | 118.14 Mn |
| Jun 30, 2025 | 112.48 Mn |
| Mar 31, 2025 | 5.50 Mn |
| Dec 31, 2024 | 37.18 Mn |
| Sep 30, 2024 | 41.25 Mn |
| Jun 30, 2024 | 33.60 Mn |
| Mar 31, 2024 | 33.60 Mn |
| Dec 31, 2023 | 4.36 Mn |
| Sep 30, 2023 | 17.04 Mn |
| Jun 30, 2023 | 11.93 Mn |
| Mar 31, 2023 | 25.96 Mn |
| Dec 31, 2022 | 17.05 Mn |
| Sep 30, 2022 | 31.44 Mn |
| Dec 31, 2021 | 3.07 Mn |